Table 4.
Analyte | CSF or plasma | Association with AD pathology | Notes | Reference |
---|---|---|---|---|
α-1-microglobulin | CSF | Regional atrophy | [157] | |
Apolipoprotein CIII | CSF | Regional atrophy | [157] | |
Apolipoprotein D | CSF | Regional atrophy | [157] | |
Brain-derived neurotrophic factor | Plasma | Aβ | Neuroprotective | [165] |
Brain-derived neurotrophic factor | Plasma | NOT HV, M | Val66Met polymorphism | [164] |
CD40 antigen | CSF | Aβ | [162] | |
Chromogranin A | CSF | WBA | Aβ dependent | [159] |
Chromogranin A | CSF | MCI to AD | [166] | |
Cystatin | CSF | WBA, HA | Aβ dependent | [159] |
Factor H | CSF | CD, VE | [167] | |
Fatty acid binding protein | CSF | Aβ | [162] | |
Fatty acid binding protein | CSF | CN to MCI | [168] | |
Fatty acid binding protein | CSF | MCI to AD | [166] | |
Ferritin | CSF | Regional atrophy | Aβ independent | [157] |
Hepatocyte growth factor | CSF | Regional atrophy | Aβ independent | [157] |
Hepatocyte growth factor | CSF | Aβ | [162] | |
Interleukin 16 | CSF | Regional atrophy | [157] | |
Interleukin 6 | CSF | Regional atrophy | [157] | |
Lipoprotein A | CSF | Aβ | [162] | |
Neurofilament light | CSF | CS, CD, WMC WBA, C, HA | [160] | |
Neurogranin | CSF | CS, C, Met, HV | Aβ dependent | [158] |
Prolactin | CSF | Aβ | [162] | |
Resistin | CSF | Aβ | [162] | |
S100β | CSF | Regional atrophy | Aβ independent | [157] |
Trefoil factor 3 | CSF | WBA, HA, VE | Aβ dependent | [159] |
Vascular endothelial growth factor | CSF | WBA | Aβ dependent | [159] |
Vascular endothelial growth factor | CSF | HV, HA, CD | Neuroprotective, effect enhanced in Aβ+ | [161] |
Vascular endothelial growth factor | CSF | Aβ | [162] |
Abbreviations: CSF, cerebrospinal fluid; AD, Alzheimer’s disease; HV, hippocampal volume; M, memory; WBA, whole brain atrophy; HA, hippocampal atrophy; CD, cognitive decline; VE, ventricular expansion; CN, cognitively normal; MCI, mild cognitive impairment; CS, clinical status; WMC, white-matter change; Met, metabolism; C, cognition.